StockNews.com Begins Coverage on DBV Technologies (NASDAQ:DBVT)

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report released on Wednesday. The brokerage issued a hold rating on the stock.

Separately, HC Wainwright lowered their price target on shares of DBV Technologies from $10.00 to $5.00 and set a buy rating on the stock in a research note on Wednesday, May 8th.

DBV Technologies Stock Performance

Shares of DBVT opened at $0.60 on Wednesday. The stock has a market capitalization of $115.72 million, a P/E ratio of -1.43 and a beta of 0.73. The company’s fifty day moving average is $0.69 and its two-hundred day moving average is $0.80. DBV Technologies has a 1 year low of $0.42 and a 1 year high of $2.26.

DBV Technologies’s stock is scheduled to reverse split on Monday, June 3rd. The 1-2 reverse split was announced on Monday, June 3rd. The number of shares owned by shareholders will be adjusted after the market closes on Monday, June 3rd.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.10. The company had revenue of $8.88 million for the quarter, compared to analysts’ expectations of $1.10 million. DBV Technologies had a negative net margin of 530.89% and a negative return on equity of 56.76%. During the same period in the previous year, the company posted ($0.23) EPS. Sell-side analysts predict that DBV Technologies will post -0.61 EPS for the current year.

Hedge Funds Weigh In On DBV Technologies

Institutional investors and hedge funds have recently made changes to their positions in the stock. Yiheng Capital Management L.P. boosted its position in shares of DBV Technologies by 6.2% in the 1st quarter. Yiheng Capital Management L.P. now owns 5,568,909 shares of the company’s stock worth $4,172,000 after buying an additional 327,345 shares in the last quarter. Cowen AND Company LLC purchased a new stake in shares of DBV Technologies in the 4th quarter worth about $49,000. Optiver Holding B.V. boosted its position in shares of DBV Technologies by 595.2% in the 3rd quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock worth $374,000 after buying an additional 235,337 shares in the last quarter. Finally, Landscape Capital Management L.L.C. purchased a new stake in shares of DBV Technologies in the 3rd quarter worth about $94,000. 71.74% of the stock is owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.